Glycomimetics Stock Price, News & Analysis

GlycoMimetics, Inc. (Nasdaq: GLYC) reported its financial results for Q4 and the full year ended December 31, 2020. The company had cash and cash equivalents of $137.0 million as of year-end. Revenue for 2020 was $10.2 million, significantly higher than 2019, reflecting progress in collaborations for uproleselan and GMI-1687. The pivotal trial for uproleselan continues to enroll patients, with completion expected in H2 2021. The company shifted focus from rivipansel to GMI-1687, which may better suit outpatient care for sickle cell patients.

GlycoMimetics, Inc. (Nasdaq: GLYC) announces participation in three virtual healthcare conferences in March 2021. Key events include:

• Cowen 41st Annual Health Care Conference: March 1-4, featuring Eric Feldman on a Leukemias Panel on March 3.
• H.C. Wainwright Global Life Sciences Conference: March 9-10, with CEO Rachel King presenting a corporate overview.
• 33rd Annual Virtual Roth Conference: March 15-17, where Rachel King will again present.

GlycoMimetics focuses on novel glycomimetic drugs for hematology-oncology.

GlycoMimetics, Inc. (Nasdaq: GLYC) will host a conference call on March 2, 2021, at 8:30 a.m. ET to report its fourth quarter and year-end 2020 financial results. The call can be accessed domestically at (844) 413-7154 or internationally at (216) 562-0466 with participant code 1034166. A webcast replay will be available for 30 days post-call. The company focuses on developing novel glycomimetic drugs for unmet medical needs in hematology-oncology, including the evaluation of uproleselan in clinical trials.

GlycoMimetics, Inc. (Nasdaq: GLYC) has promoted Eric Feldman, M.D., to Senior Vice President and Chief Medical Officer, effective immediately. Dr. Feldman, previously Vice President, Global Clinical Development, is noted for his expertise in developing therapies for leukemias. He will lead the uproleselan program, currently in Phase 3 trials. Dr. Helen Thackray, former Chief Medical Officer, will leave the company after 15 years. Uproleselan, an investigational treatment for AML, has received Breakthrough Therapy designation from the FDA, showing promising results in clinical trials.

GlycoMimetics (Nasdaq: GLYC) presented new data on rivipansel at the 62nd ASH Annual Meeting, confirming its efficacy in treating acute vaso-occlusive crises (VOC) in sickle cell disease. The analysis from an Open Label Extension trial revealed that early treatment with rivipansel resulted in a median hospital stay of 80.89 hours, compared to 103.97 hours for placebo, a significant difference. The pediatric data showed a reduction of 29.3 hours in the median time to resolution of pain. CEO Rachel King emphasized ongoing FDA interactions for future clinical development.

GlycoMimetics (Nasdaq: GLYC) announced promising results for its investigational drug uproleselan at the 62nd ASH Annual Meeting. The drug significantly reduced tumor burden and improved survival rates in animal models of acute myeloid leukemia (AML) when combined with venetoclax and a hypomethylating agent. CEO Rachel King emphasized the potential for further clinical trials to explore this combination. Uproleselan is currently in Phase 3 development for AML and has received Breakthrough Therapy designation from the FDA.

GlycoMimetics, Inc. (Nasdaq: GLYC) announced that CEO Rachel King will present at the Stifel 2020 Virtual Healthcare Conference on November 17 and the Jefferies Virtual London Healthcare Conference on November 19. The presentations can be accessed on the company's website under the Investors tab. GlycoMimetics is focused on innovative glycomimetic drugs for unmet medical needs, including treatments for acute myeloid leukemia and sickle cell disease. Uproleselan is in a Phase 3 trial for relapsed/refractory AML, and Rivipansel is investigating acute VOC in SCD.

GlycoMimetics, Inc. (Nasdaq: GLYC) reported Q3 2020 financial results, highlighting cash and equivalents of $142.9 million. The Phase 3 trials for uproleselan in AML are progressing, with enrollment completion projected in H2 2021. Significant data from rivipansel's Phase 3 RESET trial indicates improved discharge times in early crisis treatment. General and administrative expenses rose to $4.1 million, while R&D expenses remained stable at $10.7 million for Q3. CEO Rachel King emphasized the company's commitment to advancing its pipeline amidst the ongoing pandemic.

GlycoMimetics, Inc. (Nasdaq: GLYC) announced that five abstracts from its clinical portfolio have been accepted for presentations at the 62nd ASH Annual Meeting, scheduled for December 5-8, 2020. Key highlights include positive findings from the Phase 3 RESET study of rivipansel, indicating shorter hospital stays and reduced opioid use for sickle cell disease patients. Additionally, GMI-1687's potential for intravenous and subcutaneous administration was presented, alongside data on uproleselan's efficacy in acute myeloid leukemia (AML). These presentations suggest novel treatment pathways for unmet medical needs.